Logo yposkesi
waves image
waves image

Driving innovation in high quality viral vector manufacturing for gene therapy developers

Yposkesi offers extensive GMP manufacturing capabilities for AAV and lentiviral vector production.

About us
Latest News
Yposkesi’s bioproduction ‘Boost’ project is selected for France Relance scheme.

Increasing accessibility to new gene therapies


Time is of essence in clinical development of new therapies, and manufacturing is often a real bottleneck for gene therapy products.  At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. The sheer size of our GMP facility, dedicated manpower and expertise enable us to readily accommodate new projects and meet the on-time demands of those clients breaking ground in therapeutic treatments.

Read More


There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products. As a leading CDMO (Contract Development Manufacturing Organization), Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on the evolving needs of our clients and their requirements for a committed, sustainable and competitive AAV and lentiviral vector supplier.

Read More

Integrated Services

Yposkesi provides integrated services with both technical expertise and a long-term commitment to quality. Our services encompass process development, GMP  manufacturing of AAV and lentiviral vectors, Fill&Finish, QC, QA and regulatory support. We aim to establish an open and trustworthy relationship with clients with the ultimate objective of supporting them in reducing time-to-market and ensuring an uninterrupted supply of viral vectors.

Read More

About Us

Yposkesi is a best-in-class Contract Development and Manufacturing Organization (CDMO) for companies developing cell and gene therapies. Yposkesi offers end-to-end high quality and on-time viral vector CDMO services from clinical Phase I/II through to commercial manufacturing.

As of March 2021, Yposkesi welcomed SK Pharmteco, a global CDMO player, as its main shareholder. Yposkesi’s current 50,000ft2 (approx. 5,000m2) facility operates multiple manufacturing suites for bulk drug substance (up to 1000L) and Fill & Finish.

By 2023, Yposkesi will increase its global footprint to 100,000ft2 (approx. 10,000m2) with a second large-scale facility designed for EMA and FDA compliance. Yposkesi employs 185 staff and is located on the Genopole Innovation Campus in Corbeil-Essonnes (South of Paris), France.

About us

Bioprocess development (USP & DSP)

We use innovation to reach new heights in production efficiency.


GMP manufacturing of clinical and commercial viral vector batches

Our extensive AAV and lentiviral vector manufacturing capacity helps ensure on-time deliver.


Analytical development, assays qualification & validation

Our experts aim to satisfy all your analytical needs with high quality.


Fill & Finish

We offer two options for Fill&Finish: Crystal® Closed Vial Technology or glass vials.


Regulatory support

We provide strategic, technical and regulatory support.


Would you like to know more?

Contact us